Aarti Drugs Limited Stock Price Today (NSE: AARTIDRUGS)
Fundamental Score
Aarti Drugs Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Aarti Drugs Limited share price today is ₹424.30, down 0.48% on NSE/BSE as of 16 September 2026. Aarti Drugs Limited (AARTIDRUGS) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹3.87K (Cr). The 52-week high for AARTIDRUGS share price is ₹534.55 and the 52-week low is ₹318.95. At a P/E ratio of 20.27x, AARTIDRUGS is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 13.36% and a debt-to-equity ratio of 0.37.
Aarti Drugs Limited Share Price Chart — NSE/BSE Historical Performance
Aarti Drugs Limited share price chart: 0.21% return over the past month. 52-week high ₹534.55, 52-week low ₹318.95.
Aarti Drugs Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹428.00 | ₹431.70 | ₹411.00 | ₹424.30 | 1.38L (Cr) | |
| ₹428.00 | ₹439.90 | ₹424.00 | ₹426.35 | 1.44L (Cr) | |
| ₹437.00 | ₹444.00 | ₹426.15 | ₹428.50 | 1.73L (Cr) | |
| ₹426.25 | ₹439.40 | ₹422.35 | ₹437.00 | 2.55L (Cr) | |
| ₹421.50 | ₹430.95 | ₹421.50 | ₹423.45 | 1.08L (Cr) | |
| ₹421.50 | ₹427.90 | ₹419.20 | ₹421.50 | 60.74K (Cr) | |
| ₹433.25 | ₹434.70 | ₹419.25 | ₹423.00 | 94.39K (Cr) | |
| ₹429.25 | ₹443.75 | ₹426.20 | ₹431.65 | 2.50L (Cr) | |
| ₹420.85 | ₹440.60 | ₹419.50 | ₹425.85 | 3.80L (Cr) | |
| ₹430.00 | ₹430.00 | ₹415.85 | ₹417.80 | 1.71L (Cr) |
Aarti Drugs Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹411.85 | ₹444.00 | ₹410.30 | ₹424.30 | +3.02% | |
| ₹424.00 | ₹453.65 | ₹404.50 | ₹411.70 | -2.90% | |
| ₹377.50 | ₹435.25 | ₹374.80 | ₹422.75 | +11.99% | |
| ₹385.90 | ₹391.05 | ₹365.00 | ₹377.90 | -2.07% | |
| ₹376.30 | ₹407.20 | ₹356.10 | ₹380.40 | +1.09% | |
| ₹330.00 | ₹385.30 | ₹322.05 | ₹376.30 | +14.03% | |
| ₹350.00 | ₹364.80 | ₹318.95 | ₹319.75 | -8.64% | |
| ₹381.15 | ₹422.20 | ₹354.40 | ₹367.00 | -3.71% | |
| ₹412.55 | ₹417.70 | ₹362.25 | ₹381.05 | -7.64% | |
| ₹424.85 | ₹425.30 | ₹376.50 | ₹411.65 | -3.11% | |
| ₹491.10 | ₹534.00 | ₹423.50 | ₹424.85 | -13.49% | |
| ₹486.50 | ₹530.15 | ₹478.00 | ₹491.10 | +0.95% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Aarti Drugs Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Aarti Drugs Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of AARTIDRUGS across key market metrics for learning purposes.
Positive Indicators
6 factors identified
Attractive Valuation (P/E: 20.27 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Strong Revenue Growth (19.01%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Interest Coverage (7.26x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Healthy Liquidity Position (Current Ratio: 1.60)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Cash Generation (₹167.17 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (54.72%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Risk Factors
3 factors identified
Limited Growth History (3.55% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Earnings Growth (-6.62% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-7.02% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Aarti Drugs Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Aarti Drugs Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Aarti Drugs LimitedAarti Drugs Lim...Selected✓ AARTIDRUGS • 524348 | 36.3/100 | ₹424.30₹424 | ₹3872.59₹3872.59 | 20.27Average 20.3 Average | 13.36%Average 13.36% Average | 13.47%Average 13.47% Average | 0.37Excellent 0.4 Excellent | -7.02%Poor -7.02% Poor | 3.55%Average 3.55% Average | 0.47% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1864.90₹1865 | ₹447445.46₹447445.46 | 37.00Average 37.0 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9488.00₹9488 | ₹251432.00₹251432.00 | 86.09Average 86.1 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4930.00₹4930 | ₹166860.78₹166860.78 | 78.75Average 78.8 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1127.40₹1127 | ₹112514.52₹112514.52 | 25.13Average 25.1 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1363.10₹1363 | ₹110118.03₹110118.03 | 32.66Average 32.7 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1937.00₹1937 | ₹104646.43₹104646.43 | 95.61Average 95.6 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1698.90₹1699 | ₹97754.71₹97754.71 | 26.55Average 26.5 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.00₹2100 | ₹96022.50₹96022.50 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1145.00₹1145 | ₹95607.50₹95607.50 | 29.59Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2265.00₹2265 | ₹93544.50₹93544.50 | 45.77Average 45.8 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price447445.46 Cr
- Divi's Laboratories Limited share price251432.00 Cr
- Torrent Pharmaceuticals Limited share price166860.78 Cr
- Zydus Lifesciences Limited share price112514.52 Cr
- Cipla Limited share price110118.03 Cr
Aarti Drugs Limited PE Ratio History
Historical price-to-earnings ratio for AARTIDRUGS — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹18.35 | ₹411.65 | 22.4x |
| FY 2024 | ₹18.56 | ₹460.40 | 24.8x |
| FY 2023 | ₹17.97 | ₹489.20 | 27.2x |
| FY 2022 | ₹22.14 | ₹460.10 | 20.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Aarti Drugs Limited Dividend History
Annual cash dividends paid by AARTIDRUGS — dividend yield 0.47%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹9.06 Cr |
| FY 2024 | ₹9.27 Cr |
| FY 2023 | ₹9.40 Cr |
| FY 2022 | ₹9.51 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Aarti Drugs Limited Quarterly Performance
Latest quarterly metrics for AARTIDRUGS — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
19.01%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-6.94%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
3.55%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-7.02%
Compounded annual net profit growth over 5 years
Aarti Drugs Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for AARTIDRUGS — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Aarti Drugs Limited Financial Statements
Annual income statement, balance sheet and cash flow for Aarti Drugs Limited (AARTIDRUGS) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Aarti Drugs Limited
About AARTIDRUGS (Aarti Drugs Limited)
Aarti Drugs Ltd is a prominent Indian pharmaceutical company engaged in the development, manufacturing, and global distribution of a diverse range of pharmaceutical products. With ...a strong emphasis on innovation and quality, the company operates through its subsidiaries, focusing on active pharmaceutical ingredients (APIs), crucial intermediates, specialized chemicals, and finished formulations. Their commitment to research and development is evident in their continuous efforts to enhance existing processes and introduce novel molecules, positioning them as a reliable partner for pharmaceutical companies worldwide. Aarti Drugs strives to uphold the highest standards of regulatory compliance and environmental responsibility in all aspects of their operations. The company's API portfolio encompasses a wide spectrum of therapeutic categories, including anti-inflammatory, antibiotic, and anti-infective agents. This extensive range allows Aarti Drugs to cater to the varied needs of their clientele, which includes generic pharmaceutical manufacturers and branded pharmaceutical companies. By vertically integrating their operations, from the production of key starting materials to the final API, Aarti Drugs maintains rigorous control over quality and supply chain efficiency. Their dedication to meeting stringent international quality standards has earned them a reputation for reliability and consistency in delivering high-quality products. Aarti Drugs extends its expertise beyond APIs, offering specialized chemical solutions tailored to the specific needs of its customers. Their commitment to providing comprehensive pharmaceutical solutions is further reinforced through their manufacturing and marketing of finished formulations. With a focus on affordability and accessibility, Aarti Drugs contributes to improving healthcare outcomes by offering cost-effective medications. Their dedication to innovation, quality, and customer satisfaction cements their position as a trusted and valuable player in the global pharmaceutical landscape.
Company Details
Key Leadership
AARTIDRUGS Share Price: Frequently Asked Questions
What is the current share price of Aarti Drugs Limited?
Aarti Drugs Limited (AARTIDRUGS) trades at ₹424.30 on NSE and BSE. Market cap ₹3.87K (Cr). Educational data only.
What is the P/E ratio of Aarti Drugs Limited?
Aarti Drugs Limited has a P/E of 20.27x vs industry average 34.89x.
What is the Bull Run score for Aarti Drugs Limited?
Aarti Drugs Limited has a Bull Run score of 36.3/100 based on 25+ financial parameters.
Does Aarti Drugs Limited pay dividends?
Aarti Drugs Limited has a dividend yield of 0.47%. Past dividends don't guarantee future payments.
What is the ROE of Aarti Drugs Limited?
Aarti Drugs Limited has ROE of 13.36%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Aarti Drugs Limited?
Aarti Drugs Limited has debt-to-equity of 0.37.
Is Aarti Drugs Limited a good investment?
Bull Run gives Aarti Drugs Limited a score of 36.3/100. This is not investment advice — consult a SEBI-registered advisor.